MedTrace Logo

DP-R208 Pharmacokinetic Study

NCT02709187 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2016-06-08

No results posted yet for this study

Summary

An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R208 (Candesartan cilexetil 8mg/Rosuvastatin 10mg), a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers

Conditions

  • Healthy

Interventions

DRUG

DP-R208

Investigational product is prescribed to all of randomized subjects

DRUG

Candesartan cilexetil

Investigational product is prescribed to all of randomized subjects

DRUG

Rosuvastatin

Investigational product is prescribed to all of randomized subjects

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-05-31
Completion
2016-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709187 on ClinicalTrials.gov